INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.

EyePoint shares fell 66.98% to $4.87 on Aug. 17, 2026, after its first Phase 3 trial of DURAVYU failed to meet the BCVA endpoint in the full dataset; after the second Phase 3 trial also missed its primary endpoint, shares fell 85.28% to $0.44 on Oct. 19. EyePoint ended its late-stage wet AMD program and announced a 53% workforce reduction, refocusing on diabetic macular edema programs. Pomerantz LLP says it is investigating whether EyePoint and certain officers or directors engaged in securities fraud or other unlawful business practices; the announcement is an investigation, not a finding of misconduct.

Analysis

The securities investigation adds a legal overhang, but the core valuation risk is now whether EyePoint can fund and execute its remaining diabetic macular edema programs—not whether the complaint headline produces an immediate liability. An investigation is not a finding of wrongdoing, and absent a filed complaint, credible damages estimate, or insurance information, its near-term financial impact is unquantifiable. The larger market implication is a higher perceived financing and execution risk premium for EyePoint; any need to raise capital could be especially dilutive after the share-price collapse. Over the next 1–3 months, watch for litigation filings, cash/runway disclosures, restructuring costs, and updated DME timelines. Over 6–18 months, clinical evidence and financing access—not the legal headline—should dominate outcomes. Regeneron’s position in wet AMD is comparatively insulated: the failed program does not, by itself, establish a measurable earnings benefit for REGN or a durable change in competitive dynamics. Contrarian view: after two severe trial-related repricings, the lawsuit may be low-incremental-information news, but that does not make EYPT attractive; the remaining pipeline is a binary, potentially financing-dependent option whose value cannot be assessed from this article. Reassess if EyePoint provides a credible cash runway and DME plan; thesis weakens if subsequent filings identify material claims or disclosures show inadequate funding.

Key Decisions for Investors

• Avoid treating the investigation headline as a fresh standalone short catalyst: much of the fundamental damage described is already reflected in the preceding repricing, while shorting a highly distressed, potentially volatile name carries squeeze and liquidity risk.
• Keep EYPT on a watchlist rather than initiating a directional position until verifying cash and equivalents, quarterly burn, restructuring charges, debt or other obligations, and management’s funded timeline for the DME programs.
• Monitor court dockets for an actual complaint, named claims, alleged loss methodology, and any company response. Escalate the legal-risk assessment only if filings or disclosures establish plausible material exposure; the investigation announcement alone does not do so.
• Do not use REGN as an automatic offset or beneficiary trade: the article provides no evidence that EyePoint’s program termination changes Regeneron’s near-term revenue, pricing, or guidance.